Eniola should frame the venture unambiguously as a 'Drug Discovery Platform' — the exact phrase Servier uses for its third Golden Ticket priority area — and lead every section with this label, not 'drug resistance predictor.' The core pitch is that ESM-2 delta-embeddings eliminate the crystallography bottleneck that constrains Servier's own hit-to-lead and lead-optimisation pipelines: 100% mutation coverage vs. 17.6% for structure-dependent tools, with comparable AUROC to published SOTA. The Servier alignment is uniquely credible: Servier is already named on the venture's roadmap as a named pilot target and is cited as a named partner in other submitted applications — the incubator pitch is therefore 'we chose Paris-Saclay and Servier before this call existed.' Spartners residency should be positioned as the infrastructure bridge to execute the Servier pilot in-house, converting a planned B2B collaboration into a co-located, co-developed proof of commercial value.